Nephrogenic system fibrosis: A radiologist's practical perspective

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

This manuscript will provide the background current understanding of Nephrogenic Systemic Fibrosis (NSF) necessary to be appreciated by radiologists who are practicing cross-sectional imaging including gadolinium based contrast agent (Gd-CA) enhanced MRI. Examination of the known risk factors for NSF provides a practical list of considerations including an appreciation of the degree of patient renal function, or dysfunction, and the type and dose of Gd-CA used. Data is presented to argue that we must consider not only the one-time dose, but particularly the cumulative Gd-CA life-time dose administered to a patient. Using the foundation of known risk factors for NSF, we can then assemble a working list of strategies that can be utilized in an imaging practice to minimize the risk of NSF for all patients, including those at highest risk for this disorder. This list includes a discussion of high stability Gd-CAs, cumulative dose monitoring and limits, dialysis, and more specific documentation in the medical records. Finally, the issues required to understand the information that should be provided to the patient prior to obtaining informed consent are discussed. The objectives of an informed consent is to ensure that the patient is properly informed and involved in the decision to proceed with a contrast enhanced MRI, and to provide documentation to establish that the medical facilities and the radiologist are themselves well-versed in the risks and benefits when making the decision to use contrast enhanced MRI for particular patients. The process of informed consent requires that there be a consideration of the risks of not performing the contrast enhanced MRI, or the relative risk of performing another test, particularly a contrast enhanced CT. This requires an appreciation of the risks of CT-related ionizing radiation and cancer, and the risk of iodine based contrast agents (I-CA) and contrast induced nephropathy (CIN). Data is presented to show that many, and perhaps the vast majority, of renal dysfunction patients are at greater risk of harm from I-CA related to CT as compared to high stability Gd-CAs used for MRI.

Original languageEnglish (US)
Pages (from-to)220-224
Number of pages5
JournalEuropean Journal of Radiology
Volume66
Issue number2
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Nephrogenic Fibrosing Dermopathy
Fibrosis
Contrast Media
Gadolinium
Informed Consent
Iodine
Documentation
Kidney
Midazolam
Ionizing Radiation
Radiologists
Medical Records
Dialysis
Decision Making
Neoplasms

Keywords

  • CIN
  • Contrast induced nephropathy
  • CT
  • Dialysis
  • Gadolinium
  • Gadolinium based contrast agents
  • Gadolinium-chelates
  • Informed consent
  • Iodinated contrast
  • Kidney
  • Magnetic resonance imaging
  • MRI
  • Nephrogenic systemic fibrosis
  • NSF
  • Renal

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Nephrogenic system fibrosis : A radiologist's practical perspective. / Martin, Diego R.

In: European Journal of Radiology, Vol. 66, No. 2, 05.2008, p. 220-224.

Research output: Contribution to journalArticle

@article{c4b92216c1604c2ea8b00c185c0311d0,
title = "Nephrogenic system fibrosis: A radiologist's practical perspective",
abstract = "This manuscript will provide the background current understanding of Nephrogenic Systemic Fibrosis (NSF) necessary to be appreciated by radiologists who are practicing cross-sectional imaging including gadolinium based contrast agent (Gd-CA) enhanced MRI. Examination of the known risk factors for NSF provides a practical list of considerations including an appreciation of the degree of patient renal function, or dysfunction, and the type and dose of Gd-CA used. Data is presented to argue that we must consider not only the one-time dose, but particularly the cumulative Gd-CA life-time dose administered to a patient. Using the foundation of known risk factors for NSF, we can then assemble a working list of strategies that can be utilized in an imaging practice to minimize the risk of NSF for all patients, including those at highest risk for this disorder. This list includes a discussion of high stability Gd-CAs, cumulative dose monitoring and limits, dialysis, and more specific documentation in the medical records. Finally, the issues required to understand the information that should be provided to the patient prior to obtaining informed consent are discussed. The objectives of an informed consent is to ensure that the patient is properly informed and involved in the decision to proceed with a contrast enhanced MRI, and to provide documentation to establish that the medical facilities and the radiologist are themselves well-versed in the risks and benefits when making the decision to use contrast enhanced MRI for particular patients. The process of informed consent requires that there be a consideration of the risks of not performing the contrast enhanced MRI, or the relative risk of performing another test, particularly a contrast enhanced CT. This requires an appreciation of the risks of CT-related ionizing radiation and cancer, and the risk of iodine based contrast agents (I-CA) and contrast induced nephropathy (CIN). Data is presented to show that many, and perhaps the vast majority, of renal dysfunction patients are at greater risk of harm from I-CA related to CT as compared to high stability Gd-CAs used for MRI.",
keywords = "CIN, Contrast induced nephropathy, CT, Dialysis, Gadolinium, Gadolinium based contrast agents, Gadolinium-chelates, Informed consent, Iodinated contrast, Kidney, Magnetic resonance imaging, MRI, Nephrogenic systemic fibrosis, NSF, Renal",
author = "Martin, {Diego R}",
year = "2008",
month = "5",
doi = "10.1016/j.ejrad.2008.01.029",
language = "English (US)",
volume = "66",
pages = "220--224",
journal = "Journal of Medical Imaging",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Nephrogenic system fibrosis

T2 - A radiologist's practical perspective

AU - Martin, Diego R

PY - 2008/5

Y1 - 2008/5

N2 - This manuscript will provide the background current understanding of Nephrogenic Systemic Fibrosis (NSF) necessary to be appreciated by radiologists who are practicing cross-sectional imaging including gadolinium based contrast agent (Gd-CA) enhanced MRI. Examination of the known risk factors for NSF provides a practical list of considerations including an appreciation of the degree of patient renal function, or dysfunction, and the type and dose of Gd-CA used. Data is presented to argue that we must consider not only the one-time dose, but particularly the cumulative Gd-CA life-time dose administered to a patient. Using the foundation of known risk factors for NSF, we can then assemble a working list of strategies that can be utilized in an imaging practice to minimize the risk of NSF for all patients, including those at highest risk for this disorder. This list includes a discussion of high stability Gd-CAs, cumulative dose monitoring and limits, dialysis, and more specific documentation in the medical records. Finally, the issues required to understand the information that should be provided to the patient prior to obtaining informed consent are discussed. The objectives of an informed consent is to ensure that the patient is properly informed and involved in the decision to proceed with a contrast enhanced MRI, and to provide documentation to establish that the medical facilities and the radiologist are themselves well-versed in the risks and benefits when making the decision to use contrast enhanced MRI for particular patients. The process of informed consent requires that there be a consideration of the risks of not performing the contrast enhanced MRI, or the relative risk of performing another test, particularly a contrast enhanced CT. This requires an appreciation of the risks of CT-related ionizing radiation and cancer, and the risk of iodine based contrast agents (I-CA) and contrast induced nephropathy (CIN). Data is presented to show that many, and perhaps the vast majority, of renal dysfunction patients are at greater risk of harm from I-CA related to CT as compared to high stability Gd-CAs used for MRI.

AB - This manuscript will provide the background current understanding of Nephrogenic Systemic Fibrosis (NSF) necessary to be appreciated by radiologists who are practicing cross-sectional imaging including gadolinium based contrast agent (Gd-CA) enhanced MRI. Examination of the known risk factors for NSF provides a practical list of considerations including an appreciation of the degree of patient renal function, or dysfunction, and the type and dose of Gd-CA used. Data is presented to argue that we must consider not only the one-time dose, but particularly the cumulative Gd-CA life-time dose administered to a patient. Using the foundation of known risk factors for NSF, we can then assemble a working list of strategies that can be utilized in an imaging practice to minimize the risk of NSF for all patients, including those at highest risk for this disorder. This list includes a discussion of high stability Gd-CAs, cumulative dose monitoring and limits, dialysis, and more specific documentation in the medical records. Finally, the issues required to understand the information that should be provided to the patient prior to obtaining informed consent are discussed. The objectives of an informed consent is to ensure that the patient is properly informed and involved in the decision to proceed with a contrast enhanced MRI, and to provide documentation to establish that the medical facilities and the radiologist are themselves well-versed in the risks and benefits when making the decision to use contrast enhanced MRI for particular patients. The process of informed consent requires that there be a consideration of the risks of not performing the contrast enhanced MRI, or the relative risk of performing another test, particularly a contrast enhanced CT. This requires an appreciation of the risks of CT-related ionizing radiation and cancer, and the risk of iodine based contrast agents (I-CA) and contrast induced nephropathy (CIN). Data is presented to show that many, and perhaps the vast majority, of renal dysfunction patients are at greater risk of harm from I-CA related to CT as compared to high stability Gd-CAs used for MRI.

KW - CIN

KW - Contrast induced nephropathy

KW - CT

KW - Dialysis

KW - Gadolinium

KW - Gadolinium based contrast agents

KW - Gadolinium-chelates

KW - Informed consent

KW - Iodinated contrast

KW - Kidney

KW - Magnetic resonance imaging

KW - MRI

KW - Nephrogenic systemic fibrosis

KW - NSF

KW - Renal

UR - http://www.scopus.com/inward/record.url?scp=43049130289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049130289&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2008.01.029

DO - 10.1016/j.ejrad.2008.01.029

M3 - Article

C2 - 18321672

AN - SCOPUS:43049130289

VL - 66

SP - 220

EP - 224

JO - Journal of Medical Imaging

JF - Journal of Medical Imaging

SN - 0720-048X

IS - 2

ER -